ESMO 2023 | 5-year monarchE results: abemaciclib + ET in high-risk EBC

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, dsicusses the 5-year efficacy results of the Phase III monarchE (NCT03155997) trial evaluating adjuvant abemaciclib combined with endocrine therapy (ET) in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer. The study included two cohorts with different risk criteria. With a median follow-up of 54 months, the benefit of abemaciclib persisted, demonstrating a 5-year absolute improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) rates. The abemaciclib arm continued to reduce the risk of recurrence well beyond the 2-year treatment period, supporting its use in high-risk early breast cancer. Overall-survival (OS) data are evolving in favor of abemaciclib, with continued follow-up. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.